metformin has been researched along with Nasopharyngitis in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Nasopharyngitis: Inflammation of the NASOPHARYNX, usually including its mucosa, related lymphoid structure, and glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with type 2 diabetes, empagliflozin resulted in dose-dependent, clinically meaningful reductions in HbA1c and FPG, and reductions in body weight compared with placebo." | 5.17 | A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. ( Ferrannini, E; Hantel, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ, 2013) |
| " The overall frequency of adverse events was similar among the groups." | 2.84 | Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes. ( Kaku, K; Katou, M; Kinugawa, Y; Nishiyama, Y; Sumino, S, 2017) |
| "Significant lowering effects on upper respiratory tract infection were found when taspoglutide versus placebo (OR=0." | 2.53 | [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis]. ( Li, ZX; Sun, F; Wu, SS; Yang, ZR; Zhan, SY, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taneda, S | 1 |
| Hyllested-Winge, J | 1 |
| Gall, MA | 1 |
| Kaneko, S | 1 |
| Hirao, K | 1 |
| Li, ZX | 1 |
| Wu, SS | 1 |
| Yang, ZR | 1 |
| Zhan, SY | 1 |
| Sun, F | 1 |
| Kaku, K | 1 |
| Sumino, S | 1 |
| Katou, M | 1 |
| Nishiyama, Y | 1 |
| Kinugawa, Y | 1 |
| Ferrannini, E | 1 |
| Seman, L | 1 |
| Seewaldt-Becker, E | 1 |
| Hantel, S | 1 |
| Pinnetti, S | 1 |
| Woerle, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL)[NCT01059812] | Phase 3 | 424 participants (Actual) | Interventional | 2010-02-01 | Completed | ||
| SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)[NCT02798744] | Phase 4 | 68 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study[NCT02686476] | 100 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation: a Randomized Controlled Trial[NCT05042505] | 100 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in body weight after 26 weeks of treatment. (NCT01059812)
Timeframe: Week 0, Week 26
| Intervention | kg (Mean) |
|---|---|
| IDegAsp BID | 1.1 |
| BIAsp 30 BID | 1.4 |
Change from baseline in HbA1c after 26 weeks of treatment. (NCT01059812)
Timeframe: Week 0, Week 26
| Intervention | percentage of glycosylated haemoglobin (Mean) |
|---|---|
| IDegAsp BID | -1.38 |
| BIAsp 30 BID | -1.42 |
Mean of SMPG at 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast. (NCT01059812)
Timeframe: Week 26
| Intervention | mmol/L (Mean) |
|---|---|
| IDegAsp BID | 7.6 |
| BIAsp 30 BID | 7.9 |
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol. (NCT01059812)
Timeframe: Week 0 to Week 26 + 7 days follow up
| Intervention | Episodes/100 years of patient exposure (Number) |
|---|---|
| IDegAsp BID | 956 |
| BIAsp 30 BID | 952 |
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occuring between 00:01 and 05:59 a.m. (NCT01059812)
Timeframe: Week 0 to Week 26 + 7 days follow up
| Intervention | Episodes/100 years of patient exposure (Number) |
|---|---|
| IDegAsp BID | 111 |
| BIAsp 30 BID | 155 |
1 review available for metformin and Nasopharyngitis
| Article | Year |
|---|---|
[Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide- | 2016 |
3 trials available for metformin and Nasopharyngitis
| Article | Year |
|---|---|
Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
Topics: Aged; Asian People; Biphasic Insulins; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopath | 2017 |
Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
Topics: Acute Disease; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administrat | 2017 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |